MS
Octave Bioscience Building Evidence Base for Multiple Sclerosis Test to Support Clinical Launch
Premium
The company is aiming for a clinical launch this year of the test, which measures a panel of protein markers to assess disease activity in MS patients.
The company has slightly extended its timeline for launching a Lyme disease test to focus on marketing its COVID assay for immunocompromised individuals.
Numares, Oxford University Ink License Agreement to Develop Multimarker Multiple Sclerosis Test
Numares will develop the MS test to detect the transition from relapsing remitting multiple sclerosis to secondary progressive multiple sclerosis.
Siemens Healthineers, Novartis Ink Deal to Develop Assays With Initial Focus on MS Therapeutics
An initial program aims at the development of a serum neurofilament light chain immunoassay to support Novartis' MS and other neuroscience programs.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.